Efficiency of a Small-peptide Enteral Feeding Formula Compared to a Whole-protein Formula

Overview

An early and efficient enteral nutritional support could improve the clinical outcomes of brain injured critically ill patients. Gastrointestinal feeding intolerance defined as an increased gastric residual volume frequently occurs in these patients. Previous experimental studies have suggested that a small-peptide enteral feeding formula could promote the gastric emptying compared to a whole-protein formula. An improved gastrointestinal tolerance of enteral nutrition should allow a rapid increase in the daily caloric intake and enhance nutritional support of brain injured critically ill patients.

Full Title of Study: “Efficiency and Tolerance of a Small-peptide Enteral Feeding Formula Compared to a Whole-protein Formula in the Critically Ill Patient : a Prospective Randomized Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 2017

Detailed Description

This open-labelled prospective randomized trial aims to compare 2 groups of patients: the Study Group and the Control Group. The randomization process will concern the allocation of the type of enteral feeding formula administered for nutritional support: Peptamen® AF in the Study Group, and Sondalis® HP in the Control Group. 2 centers are involved in this study. Each patient admitted in the critical care unit will be assessed for eligibility. After written informed consent is obtained from relatives, patient without any exclusion criteria will be included in the study. The allocation of the type of enteral nutritional feeding formula will be randomized after inclusion. Enteral nutrition according to the randomization group will start within the 48 hours of admission and up to 10 days, if requested. Beyond the 10th day, all patients will receive standard enteral nutrition formula. After inclusion, data regarding efficacy and tolerance will be assessed daily up to day 10. Mortality and outcome will be assessed at day 28 and at day 60.

Interventions

  • Dietary Supplement: Peptamen® AF
    • Comparison of two types of enteral nutrition feeding: Peptamen® AF and Sondalis® HP
  • Dietary Supplement: Sondalis® HP

Arms, Groups and Cohorts

  • Active Comparator: Sondalis® HP
    • The Control Group that will receive Sondalis ® HP (a whole-peptide formula).
  • Experimental: Peptamen® AF
    • In this arm, patients have enteral nutrition with Peptamen® AF

Clinical Trial Outcome Measures

Primary Measures

  • the nutritional efficacy of a small-peptide (Peptamen AF®) to that of a whole-protein (Sondalis HP®) enteral feeding formula in traumatic and non-traumatic brain injured critically ill patients
    • Time Frame: Day3 to Day5
    • To compare the nutritional efficacy of a small-peptide (Peptamen AF®) to that of a whole-protein (Sondalis HP®) enteral feeding formula in traumatic and non-traumatic brain injured critically ill patients.

Secondary Measures

  • impact on morbidity and mortality of a small-peptide (Peptamen AF®) to that of a whole-protein (Sondalis HP®) enteral feeding formula.
    • Time Frame: Day 10

Participating in This Clinical Trial

Inclusion Criteria

  • Admission in our surgical critical care unit. – Traumatic brain injury. – Non-traumatic brain injury: stroke, intracranial and/or subarachnoid hemorrhage, subdural and/or extradural hematoma. – Expected duration of mechanical ventilation > 48 hours. Exclusion Criteria:

  • Abdominal surgery in the previous 30 days. – Pregnancy. – Breast-feeding. – Hemodynamic instability defined as infusion of norepinephrine > 3 mg/h, or epinephrine > 1 mg/h, or as increasing needs in vasopressive or inotropic drugs.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Centre Hospitalier Universitaire de Besancon
  • Collaborator
    • Nestlé Foundation
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Gilles Blasco, Principal Investigator,
  • Overall Contact(s)
    • Anne-Sophie BALON, +3381668675, annesophie.balon@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.